Related Experiment Video

Updated: Jul 4, 2026

Hyperglycemic Clamp and Hypoglycemic Clamp in Conscious Mice
07:35

Hyperglycemic Clamp and Hypoglycemic Clamp in Conscious Mice

Published on: January 26, 2024

From hyperglycemia to AGE-RAGE interaction on the cell surface: a dangerous metabolic route for diabetic patients

José Augusto Nogueira-Machado1, Miriam Martins Chaves

  • 1Hospital Santa Casa de Belo Horizonte, Núcleo de Pesquisa e Pós-Graduação, Avenue Francisco Sales, 1111, 30250-330, Belo Horizonte, MG, Brazil. nogueira.machado@pq.cnpq.br

Expert Opinion on Therapeutic Targets
|June 17, 2008
PubMed
Abstract

Insights

Controlling diabetes complications requires understanding hyperglycemia's metabolic cascade. Targeting the pathway from high blood sugar to AGE-RAGE complex formation is key for new therapies.

Area of Science:

  • Endocrinology
  • Metabolic pathways
  • Vascular complications of diabetes

Background:

  • Diabetes mellitus presents a significant public health challenge.
  • Current therapies inadequately manage vascular complications.
  • Understanding hyperglycemia-induced signaling pathways is crucial for developing new treatments.

Purpose of the Study:

  • To review the metabolic cascade in diabetes, focusing on hyperglycemia's role.
  • To emphasize therapeutic targets within the inducer and effector phases.
  • To highlight the hyperglycemia-to-AGE-RAGE axis as a potential therapeutic strategy.

Main Methods:

  • Comprehensive literature review.
  • Inclusion of historical and recent scientific publications.

Main Results:

  • Hyperglycemia activates a two-phase metabolic cascade.
  • This cascade leads to the formation of the advanced glycation end products (AGE)-receptor of advanced glycation end products (RAGE) complex.
  • This pathway is a significant contributor to diabetic complications.

Conclusions:

  • Simultaneous inhibition of multiple cascade steps is necessary.
  • Aggressive glycemic control is essential alongside pathway inhibition.
  • Targeting the AGE-RAGE axis offers a promising therapeutic avenue for diabetic vascular injury.

More Related Videos

Alternate Immersion in Glucose to Produce Prolonged Hyperglycemia in Zebrafish05:49

Alternate Immersion in Glucose to Produce Prolonged Hyperglycemia in Zebrafish

Published on: May 5, 2021

Related Concept Videos

Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is based on...
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...